Search

Your search keyword '"A. Rydzewska-Rosolowska"' showing total 132 results
Start Over Author "A. Rydzewska-Rosolowska"
132 results on '"A. Rydzewska-Rosolowska"'

2. ViSHWaS: Violence Study of Healthcare Workers and Systems—a global survey

Author

Faisal Nawaz, Daniel Martin Simadibrata, Vikas Bansal, Ramesh Adhikari, Mariam Elsaban, Rahul Kashyap, Priyadarshini Bhattacharjee, Jorge Salluh, Hassan Dawood Alli, Joanna Lee, Dattatreya Mukherjee, Tanja Kovačević, Mohammad Yasir Essar, Christos Tsagkaris, Genesis Camacho-Leon, Faizan Ahmad, Akshat Banga, Hans Mautong, Razan Alamoudi, Umme Habiba Faisal, Gaurang Bhatt, Tanya Amal, Ayushi Mendiratta, Bhaswanth Bollu, L V Simhachalam Kutikuppala, Ivan Huespe, Aisha Khalid, Mohammed Amir Rais, Alisha Lakhani, Piyush Garg, Harsha Pattnaik, Raghu Gandhi, Ramesh Pandit, Pierre Ciza N, Nimsi Barrios, Kelly Meza, Susan Okonkwo, Amuza Dhabuliwo, Hafeez Hamza, Arash Nemat, Anne Kampa, Rakhtan K Qasba, Pranjal Sharma, Taru Dutt, Pratikkumar Vekaria, Faisal A Nawaz, Salim Surani, Divya Randhawa, Rakhtan Qasba, Trupti Pandit, Ayesha Khalid, Ravina Verma, Kush Shah, John Counsell, Naresh Dasari, Melissa Schlenker, Raghavendra Tirupathi, Gowthami Sai Jagirdhar, Nancy Nagib, Benjamin Schlenker, Taha Mansoor, N Pierre Ciza, Leydi Del Lema, Susan Sheila, Bello Saifullah Muhammad, Barakat Kolawole, L V Kutikuppala, Keidy Zamora, Bikona Ghosh, Sama Soliman, Zainab Ayoob, Lina Almahmoud, Dohha Mohammed, Oyindamola Obadare, Era Mae Ramirez, Kalloush Shahed, Mohammed Yasir Essar, Sarya Swed, Temaa Alklani, Ishimwe Florent, Goodluck Nchasi, Daren Poh How, Mohamed Elfagieh, Moath Almekhlafi, Reshon Hadmon, Anasonye Emmanuel, Yosra Magdi Makki, Rodrigue Ndabashinze, Hussein Dawoud, Dimitrios Kantas, Daniella Myriam Pierre, Zeynep Pelin Orhan, Usama Oguz, Hedys Selene Mogollón, Ramesha Remy, Marija Vukoja, Srdjan Gavrilovic, Alicja Rydzewska Rosolowska, Umme Faisal, Franz Lopez, Salem Ramirez, Lisdamys Morera Gonzalez, Mohammed Alkawak, Marco Antonio Villar, Kelly Maza, Shehu Bledi, and Jonida Naska

Subjects
Medicine (General), R5-920, Infectious and parasitic diseases, RC109-216
Abstract

Objective To provide insights into the nature, risk factors, impact and existing measures for reporting and preventing violence in the healthcare system. The under-reporting of violence against healthcare workers (HCWs) globally highlights the need for increased public awareness and education.Methods The Violence Study of Healthcare Workers and Systems study used a survey questionnaire created using Research Electronic Data Capture (REDCap) forms and distributed from 6 June to 9 August 2022. Logistic regression analysis evaluated violence predictors, including gender, age, years of experience, institution type, respondent profession and night shift frequency. A χ2 test was performed to determine the association between gender and different violence forms.Results A total of 5405 responses from 79 countries were analysed. India, the USA and Venezuela were the top three contributors. Female respondents comprised 53%. The majority (45%) fell within the 26–35 age group. Medical students (21%), consultants (20%), residents/fellows (15%) and nurses (10%) constituted highest responders. Nearly 55% HCWs reported firsthand violence experience, and 16% reported violence against their colleagues. Perpetrators were identified as patients or family members in over 50% of cases, while supervisor-incited violence accounted for 16%. Around 80% stated that violence incidence either remained constant or increased during the COVID-19 pandemic. Among HCWs who experienced violence, 55% felt less motivated or more dissatisfied with their jobs afterward, and 25% expressed willingness to quit. Univariate analysis revealed that HCWs aged 26–65 years, nurses, physicians, ancillary staff, those working in public settings, with >1 year of experience, and frequent night shift workers were at significantly higher risk of experiencing violence. These results remained significant in multivariate analysis, except for the 55–65 age group, which lost statistical significance.Conclusion This global cross-sectional study highlights that a majority of HCWs have experienced violence, and the incidence either increased or remained the same during the COVID-19 pandemic. This has resulted in decreased job satisfaction.

Published
2023
Full Text
View/download PDF

4. Serum sirtuin 1 is independently associated with intact PTH among patients with chronic kidney disease

Author

Bielach-Bazyluk A, Zbroch E, Czajkowska K, Koc-Zorawska E, Kakareko K, Rydzewska-Rosolowska A, and Hryszko T

Subjects
sirtuin 1, sirt1, ckd, chronic kidney disease, parathyroid hormone, pth, Geriatrics, RC952-954.6
Abstract

Angelika Bielach-Bazyluk,1 Edyta Zbroch,2 Katarzyna Czajkowska,1 Ewa Koc-Zorawska,1 Katarzyna Kakareko,1 Alicja Rydzewska-Rosolowska,1 Tomasz Hryszko1 1 2nd Department of Nephrology and Hypertension with Dialysis Centre, Medical University, Bialystok, Poland; 2Department of Internal Medicine and Hypertension, Medical University, Bialystok, PolandCorrespondence: Angelika Bielach-Bazyluk 2nd Department of Nephrology and Hypertension with Dialysis Centre, Medical University, Sklodowskiej – Curie 24a, Bialystok, 15-276, PolandTel +48 858317872Email b.angelika@wp.plBackground: Sirtuin 1 is involved in the pathogenesis of age-related diseases.Purpose: The aim of the study was to assess the clinical and diagnostic value of serum sirtuin 1 concentration in patients with CKD.Patients and Methods: The serum sirtuin 1 level was evaluated using ELISA kit in 100 CKD patients stratified for five stages and in a control group of 24 healthy volunteers.Results: Serum sirtuin 1 concentration was higher in the CKD group compared with the control group (p< 0.05). Sirtuin 1 correlated with conventional CKD biomarkers and eGFR equations, intact parathyroid hormone (iPTH) and age (all p< 0.05). Statins, AT1 receptor antagonists and β-blockers use were associated with decreased sirtuin concentration (p< 0.05). Sirtuin 1 was able to distinguish CKD from control group with high sensitivity and specificity (93% and 87%, respectively; AUC=0.954). Surprisingly, after adjustment only iPTH concentration was an independent predictor of sirtuin 1 level.Conclusion: The association between sirtuin 1, eGFR equations and iPTH indicates its possible usefulness as a kidney function marker. In terms of iPTH being the only independent predictor of circulating sirtuin 1 it can be considered as an indirect cardiovascular risk biomarker regardless of renal function and provide additional information for patient management. Alternatively, sirtuin 1 is recognized as protective against vascular disease, and we demonstrated a positive correlation with iPTH, which may be related to accumulation of (7-84)-PTH having opposite biological effects to full-length PTH. Further studies are needed to explore the interplay between sirtuin 1, PTH and CKD-related vascular calcification as well as to assess its prognostic value in observational studies.Keywords: sirtuin 1, SIRT1, CKD, chronic kidney disease, parathyroid hormone, PTH

Published
2021

5. The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and αKlotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis

Author

Zbroch E, Bazyluk A, Malyszko J, Koc-Zorawska E, Rydzewska-Rosolowska A, Kakareko K, and Hryszko T

Subjects
sirtuin1, αklotho, chronic kidney disease, hemodialysis, Geriatrics, RC952-954.6
Abstract

Edyta Zbroch, 1 Angelika Bazyluk, 1 Jolanta Malyszko, 2 Ewa Koc-Zorawska, 1 Alicja Rydzewska-Rosolowska, 1 Katarzyna Kakareko, 1 Tomasz Hryszko 1 1 2-nd Department of Nephrology and Hypertension with Dialysis Centre, Medical University, Bialystok, Poland; 2Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, PolandCorrespondence: Edyta Zbroch 2-nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University, Sklodowskiej Curie 24a, Bialystok 15-276, PolandTel +48 85 8317872 Email edzbroch@poczta.onet.plIntroduction: Sirtuin1 (SIRT1) acts as an anti-aging protein due to anti-apoptotic, anti-oxidative and anti-inflammatory effect and is implicated in several diseases including diabetes or cardiovascular problems. SIRT1 renal overexpression indicates oxidative stress. Similarly, αKlotho was primarily exposed as anti-aging factor. It is primary produced in kidney. It’s deficiency is associated with progression of chronic kidney disease and heart disorders.Purpose: The aim of the study was to assess the serum concentration of sirtuin1 and αKlotho in hemodialysis (HD) patients compared to healthy volunteers in regard to age, blood pressure control, residual kidney function (RKF), diabetes, cardiovascular disease, dialysis vintage and type of dialyzer.Patients and Methods: The serum level of SIRT1 and αKlotho was evaluated using ELISA tests in 103 HD patients, median age 67 years and in 21 volunteers. Blood pressure, RRF, echocardiography and dialysis parameters were assessed. HD group was divided according to the presence/absence of RKF.Results: The serum SIRT1 level was higher (28.4 vs 2.71ng/mL, p< 0.0001) and αKlotho was lower (433.9 vs 756.6pg/mL, p< 0.0001) in HD then in control group. αKlotho was lower in those without RKF (387.2 vs 486.2pg/mL, p=0.028). SIRT1 positively correlated with hemodialysis vintage. αKlotho negatively correlated with left ventricular posterior wall thickness. There was no significant relationship between SIRT1 and αKlotho level and age, blood pressure control, type of dialyzer, Kt/V and diabetes. Multivariate analysis revealed association of SIRT1 with ejection fraction (B − 0.72; p=0.32).Conclusion: Elevated SIRT1 and lower αKlotho concentration are associated with impaired kidney function. The decrease in levels of αKlotho may also indicate heart hypertrophy in hemodialysis patients. The role of anti-aging proteins, particularly SIRT1 as biomarkers/predictors of oxidative stress, inflammation and cardiovascular diseases need further examination.Keywords: sirtuin1, αKlotho, chronic kidney disease, hemodialysis

Published
2020

7. Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Aging—A Systematic Review

Author

Angelika Bielach-Bazyluk, Edyta Zbroch, Hanna Mysliwiec, Alicja Rydzewska-Rosolowska, Katarzyna Kakareko, Iwona Flisiak, and Tomasz Hryszko

Subjects
sirtuin 1, skin, aging, photoaging, Cytology, QH573-671
Abstract

Skin, as the outermost organ of the body, is constantly exposed to both intrinsic and extrinsic causative factors of aging. Intrinsic aging is related to compromised cellular proliferative capacity, and may be accelerated by harmful environmental influences with the greatest significance of ultraviolet radiation exposure, contributing not only to premature aging, but also to skin carcinogenesis. The overall skin cancer burden and steadily increasing global antiaging market provide an incentive for searching novel targets to improve skin resistance against external injury. Sirtuin 1, initially linked to extension of yeast and rodent lifespan, plays a key role in epigenetic modification of proteins, histones, and chromatin by which regulates the expression of genes implicated in the oxidative stress response and apoptosis. The spectrum of cellular pathways regulated by sirtuin 1 suggests its beneficial impact on skin aging. However, the data on its role in carcinogenesis remains controversial. The aim of this review was to discuss the relevance of sirtuin 1 in skin aging, in the context of intrinsic factors, related to genetic premature aging syndromes, as well as extrinsic modifiable ones, with the assessment of its future application. PubMed were searched from inception to 4 January 2021 for relevant papers with further search carried out on ClinicalTrials.gov. The systematic review included 46 eligible original articles. The evidence from numerous studies proves sirtuin 1 significance in both chronological and premature aging as well as its dual role in cancer development. Several botanical compounds hold the potential to improve skin aging symptoms.

Published
2021
Full Text
View/download PDF

11. Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy

Author

Irena Glowinska, Barbara Labij-Reduta, Jerzy Juzwiuk, Magdalena Lukaszewicz, Adam Pietruczuk, Agata Poplawska, Anna Daniluk-Jamro, Katarzyna Kakareko, Alicja Rydzewska-Rosolowska, Beata Naumnik, Ewa Koc-Zorawska, Marcin Zorawski, and Tomasz Hryszko

Subjects
SARS-CoV-2, vaccine, dialysis, humoral response, obesity, General Medicine
Abstract

COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccination. We performed a prospective longitudinal cohort study to determine longevity of the humoral response after SARS-CoV-2 vaccine. The study included 191 adult patients on hemodialysis and peritoneal dialysis. All participants had been vaccinated with three doses, either with BNT162b2 (Pfizer-BioNTech) (n = 109) or mRNA-1273 (Moderna) (n = 82). Anti-spike protein receptor-binding domain antibodies (anti-S IgG) were assessed using SARS-CoV-2 (RBD) IgG ELISA EIA-6150 IVD assay at baseline, on the 21st day and 43rd day, before a booster dose and two weeks thereafter. We found that before vaccination, 37.7% of the cohort had anti-S IgG titres concordant with seroconversion. After two-dose vaccination, seroconversion occurred in 97% of patients. The booster dose evoked a ~12-fold increase in antibody level. Obesity increased more than two-fold the odds for a decrease in anti-S IgG. Previous COVID-19 infection enhanced longevity of the humoral response following vaccination. In patients with previous COVID-19 infection, the BNT162b2 vaccine was associated with a higher odds of anti-S IgG waning compared to the mRNA-1273 vaccine. In conclusion, we report that obesity predisposes patients to protective antibody waning, hybrid immunity enhances odds for higher anti-S IgG concentrations and vaccine efficacy may be influenced by previous SARS-CoV-2 infection. The results might provide a rationale for vaccination protocol design.

Published
2022
Full Text
View/download PDF

12. Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy

Author

Glowinska, Irena, primary, Labij-Reduta, Barbara, additional, Juzwiuk, Jerzy, additional, Lukaszewicz, Magdalena, additional, Pietruczuk, Adam, additional, Poplawska, Agata, additional, Daniluk-Jamro, Anna, additional, Kakareko, Katarzyna, additional, Rydzewska-Rosolowska, Alicja, additional, Naumnik, Beata, additional, Koc-Zorawska, Ewa, additional, Zorawski, Marcin, additional, and Hryszko, Tomasz, additional

Published
2022
Full Text
View/download PDF

14. The Impact of Cardiovascular Risk Factors on the Course of COVID-19

Author

Katarzyna Wilk-Sledziewska, Piotr Jan Sielatycki, Natalia Uscinska, Elżbieta Bujno, Mariusz Rosolowski, Katarzyna Kakareko, Rafal Sledziewski, Alicja Rydzewska-Rosolowska, Tomasz Hryszko, and Edyta Zbroch

Subjects
General Medicine
Abstract

Aim of the study: The aim of our review is to indicate and discuss the impact of cardiovascular risk factors, such as obesity, diabetes, lipid profile, hypertension and smoking on the course and mortality of COVID-19 infection. Background: The coronavirus disease 2019 (COVID-19) pandemic is spreading around the world and becoming a major public health crisis. All coronaviruses are known to affect the cardiovascular system. There is a strong correlation between cardiovascular risk factors and severe clinical complications, including death in COVID-19 patients. All the above-mentioned risk factors are widespread and constitute a significant worldwide health problem. Some of them are modifiable and the awareness of their connection with the COVID-19 progress may have a crucial impact on the current and possible upcoming infection. Data collection: We searched for research papers describing the impact of selected cardiovascular risk factors on the course, severity, complications and mortality of COVID-19 infection form PubMed and Google Scholar databases. Using terms, for example: “COVID-19 cardiovascular disease mortality”, “COVID-19 hypertension/diabetes mellitus/obesity/dyslipidemia”, “cardiovascular risk factors COVID-19 mortality” and other related terms listed in each subtitle. The publications were selected according to the time of their publications between January 2020 and December 2021. From the PubMed database we obtain 1552 results. Further studies were sought by manually searching reference lists of the relevant articles. Relevant articles were selected based on their title, abstract or full text. Articles were excluded if they were clearly related to another subject matter or were not published in English. The types of articles are mainly randomized controlled trial and systematic review. An additional criterion used by researchers was co-morbidities and age of patients in study groups. From a review of the publications, 105 of them were selected for this work with all subheadings included. Findings and Results: The intention of this review was to summarize current knowledge about comorbidities and development of COVID-19 infection. We tried to focus on the course and mortality of the abovementioned virus disease in patients with concomitant CV risk factors. Unfortunately, we were unable to assess the quality of data in screened papers and studies we choose because of the heterogenicity of the groups. The conducted studies had different endpoints and included different groups of patients in terms of nationality, age, race and clinical status. We decide to divide the main subjects of the research into separately described subtitles such as obesity, lipid profile, hypertension, diabetes, smoking. We believe that the studies we included and gathered are very interesting and show modern and present-day clinical data and approaches to COVID-19 infection in specific divisions of patients.

Published
2022

16. The Impact of Cardiovascular Risk Factors on the Course of COVID-19

Author

Wilk-Sledziewska, Katarzyna, primary, Sielatycki, Piotr Jan, additional, Uscinska, Natalia, additional, Bujno, Elżbieta, additional, Rosolowski, Mariusz, additional, Kakareko, Katarzyna, additional, Sledziewski, Rafal, additional, Rydzewska-Rosolowska, Alicja, additional, Hryszko, Tomasz, additional, and Zbroch, Edyta, additional

Published
2022
Full Text
View/download PDF

18. [Current nutrition recommendations for chronic kidney disease]

Author

Marta, Stachurska, Edyta, Zbroch, Katarzyna, Kakareko, Alicja, Rydzewska-Rosolowska, and Tomasz, Hryszko

Subjects
Diet, Vegetarian, Humans, Nutritional Status, Renal Insufficiency, Chronic, Glomerular Filtration Rate
Abstract

The paper discusses the current recommendations regarding the supply of individual nutrients in patients with chronic kidney disease (CKD). The recommendations include keeping the energy supply in the range of 25 to 35 kcal per kilogram of proper body weight per day, limiting the consumption of phosphorus to maximum of 1 g per day and limiting sodium to maximum of 2.3 g per day. In patients with eGFR30 ml / min / 1.73 m2, a potassium restriction should be added so that its concentration in the blood does not exceed 5 mmol / l. Experts' views on the protein restriction in CKD patients are divided. The topic is controversial and more researches are needed to see if reducing protein intake leads to malnutrition and increased risk of death in this population. The results of studies on the use of a vegetarian diet in patients with CKD seem to be promising. It is good to remember about consuming appropriate amounts of products containing trace elements such as zinc, selenium or copper, as well as polyphenols, flavonoids and antioxidants.

Published
2021

25. The Serum Concentration of Anti-Aging Proteins, Sirtuin1 and αKlotho in Patients with End-Stage Kidney Disease on Maintenance Hemodialysis

Author

Edyta, Zbroch, Angelika, Bazyluk, Jolanta, Malyszko, Ewa, Koc-Zorawska, Alicja, Rydzewska-Rosolowska, Katarzyna, Kakareko, and Tomasz, Hryszko

Subjects
Male, Aging, Heart Ventricles, Blood Pressure, Kidney, Diabetes Complications, sirtuin1, Sirtuin 1, Renal Dialysis, Humans, Klotho Proteins, Aged, Glucuronidase, Original Research, αKlotho, hemodialysis, Age Factors, Stroke Volume, Middle Aged, Cardiovascular Diseases, Echocardiography, Case-Control Studies, Kidney Failure, Chronic, Female, Biomarkers, chronic kidney disease
Abstract

Introduction Sirtuin1 (SIRT1) acts as an anti-aging protein due to anti-apoptotic, anti-oxidative and anti-inflammatory effect and is implicated in several diseases including diabetes or cardiovascular problems. SIRT1 renal overexpression indicates oxidative stress. Similarly, αKlotho was primarily exposed as anti-aging factor. It is primary produced in kidney. It’s deficiency is associated with progression of chronic kidney disease and heart disorders. Purpose The aim of the study was to assess the serum concentration of sirtuin1 and αKlotho in hemodialysis (HD) patients compared to healthy volunteers in regard to age, blood pressure control, residual kidney function (RKF), diabetes, cardiovascular disease, dialysis vintage and type of dialyzer. Patients and Methods The serum level of SIRT1 and αKlotho was evaluated using ELISA tests in 103 HD patients, median age 67 years and in 21 volunteers. Blood pressure, RRF, echocardiography and dialysis parameters were assessed. HD group was divided according to the presence/absence of RKF. Results The serum SIRT1 level was higher (28.4 vs 2.71ng/mL, p

Published
2019

28. Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients

Author

Coussement, Julien, Maggiore, Umberto, Manuel, Oriol, Scemla, Anne, López-Medrano, Francisco, Nagler, Evi, Aguado, José María, Abramowicz, Daniel, Adams, Brigitte, Agnelli, Caroline, Ailioaie, Oana, Akan, Hamdi, Amrouche, Lucile, Andrés, Amado, Anglicheau, Dany, Arnouts, Paul, Baas, Marije, Balgradean, Cristian, Bammens, Bert, Battaglia, Yuri, Baudoux, Thomas, Berto, Bert, Binet, Isabelle, Bistrup, Claus, Bonofiglio, Renzo, Bosmans, Jean-Louis, Bouatou, Yassine, Bouvier, Nicolas, Braconnier, Philippe, Bredewold, Edwin, Broeders, Nilufer, BRUNET, Philippe, Buchler, Matthias, Budde, Klemens, Buron, Fanny, Burtey, Stephane, Buscaroli, Andrea, Büttner, Stefan, Byrne, Catherine, Caldara, Rossana, Cassuto, Elisabeth, Catalano, Concetta, Cavaille, Guilhem, Corbel, Alice, Couzi, Lionel, Crespo, Marta, Daga, Sunil, Debellé, Frederic, Dedinska, Ivana, Devine, Paul, Dickenmann, Michael, Dratwa, Max, Drgona, Lubos, Durlik, Magdalena, Egidi, Maria Francesca, Errasti, Pedro, Etienne, Isabelle, Fariñas, María Carmen, Fehr, Thomas, Fernández-Ruiz, Mario, Founta, Paraskevi, Fourtounas, Konstantinos, Frangou, Eleni, Frimat, Luc, Furian, Luc, Garjau, Maria, Garrigue, Valérie, Gatault, Philippe, Geddes, Colin, Gerlinger, Paul, Gheuens, Eric, Ghisdal, Lidia, Gibbs, Paul, Giral, Magali, Girerd, Sophie, Golshayan, Dela, Gompou, Athina, Grossi, Paolo Antonio, Guglielmetti, Gabriele, Guirado, Luis, Hadaya, Karine, Hazzan, Marc, Helbert, Mark, Hellemans, Rachel, Heller, Katharina, Heemann, Uwe, Henckes, Manu, Hernandez, Domingo, Hertig, Alexandre, Hiesse, Christian, Hilbrands, Luuk, Hilton, Rachel, Hirzel, Cédric, Horcajada, Juan Pablo, Hougardy, Jean-Michel, Huynh-Do, Uyen, Idrizi, Alma, Ismaili, Khalid, Jiménez, Carlos, Jourde-Chiche, Noemie, Kamar, Nassim, Kaminski, Hannah, Kanter, Julia, Karras, Alexandre, Kemlin, Delphine, Kes, Petar, Kianda, Mireille, Klinger, Maria, Knight, Simon, Koneth, Irene, Krrashi, Anita, Kuypers, Dirk, Langlois, Anne, Lang, Philippe, Lauzurica, Ricardo, Le Moine, Alain, Lebeaux, David, Legendre, Christophe, Lemy, Anne, Len, Oscar, Liakopoulos, Vassilios, Lichodziejewska-Niemierko, Monika, Yague, Maria, Lopau, Kai, Madhoun, Philippe, Magott-Procelewska, Maria, Malik, Shafi, Montero, Anna Manonelles, Marchini, Marc, Marega, Alessandra, Mariat, Maria, Mark, Mark, Martin, Pierre-Yves, Martín, Leyre, Martín, Paloma Leticia, Massart, Annick, Matignon, Marie, Maurel, Stéphane, Mazuecos, Auxiliadora, Melexopoulou, Christina, Melilli, Edoardo, Merino, Esperanza, Mesic, Enisa, Messa, Piergiorgio, Michalak, Magdalena, Minetti, Enrico, Miserlis, Grigorios, Montejo, Miguel, Moriconi, Diego, Mottola, Clément, Mourad, Georges, Mueller, Thomas, Muñoz, Patricia, Nabokow, Alexander, Naesens, Maarten, Nikodimopoulou, Maria, Oberbauer, Rainer, Olmedo, María, Olsburgh, Jonathon, Oniscu, Gabriel, Øzbay, Lara Aygen, Palmisano, Alessandra, Papagianni, Aikaterini, Papasotiriou, Mario, Parodi, Angelica, Parry, Rob, Pascual, Julio, Flores, Isabel Pérez, Pérez-Sáez, María, Peruzzi, Licia, Petit-Hoang, Camille, Phelan, Paul, Pillebout, Evangeline, Piotti, Giovanni, Pipeleers, Lissa, Pleros, Christos, Popoola, Joyce, Pretagostini, Renzo, Psimenou, Erasmia, Puig, Josep, Rafat, Cédric, Bloudickova, Silvie Rajnochova, Bushljetikj, Irena Rambabova, Ratkovic, Marina, Redondo, Dolores, Reischig, Tomas, Robert, Thomas, Ferrero, Luis, Rroji, Merita, Rutkowski, Przemyslaw, Rydzewska-Rosolowska, Alicja, Sabé, Núria, Sahali, Dil, Salzberger, Bernd, San-Juan, Rafael, Sobrino, Beatriz Sánchez, Sandrini, Silvio, Santos, Lídia, Sava, Roxana, Schaub, Stefan, Schikowski, Johan, Schvartz, Betoul, Sester, Urban, Silva, Jose Tiago, Snanoudj, Renaud, Somenzi, Danio, Sørensen, Søren, Spanos, Georgios, Steiger, Jürg, Suwelack, Barbara, Theodoropoulou, Eleni, Thervet, Eric, Thorban, Stefan, Tognarelli, Giuliana, Tournay, Yasmina, Tricot, Leïla, Tulissi, Patrizia, Vacher-Coponat, Henri, Valerio, Maricela, Van Der Meijden, W, Van Hamersvelt, Henk, Van Laecke, Steven, Vandivinit, Alain, Vanholder, Raymond, Veroux, Massimiliano, Viklicky, Ondrej, Vigo, Emanuela, Viscoli, Claudio, Watschinger, W, Weekers, W, Welberry Smith, W, Martin, W, Zeneli, Nereida, Zervos, Angelos, Zibar, Lada, Zuber, Julien, Zukunft, Bianca, Nephrology, Department Infections Diseases, Université Libre de Bruxelles [Bruxelles] (ULB), Azienda Ospedaliero-Universitaria di Parma, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Réseau CENTAURE, Service des maladies infectieuses et tropicales [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service Néphrologie et transplantation rénale Adultes [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Bases moléculaires de la réponse aux xénobiotiques (U775 (IFR95)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut d’Électronique, de Microélectronique et de Nanotechnologie (IEMN) - UMR 8520 (IEMN), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Université Polytechnique Hauts-de-France (UPHF)-Ecole Centrale de Lille-Université Polytechnique Hauts-de-France (UPHF)-Institut supérieur de l'électronique et du numérique (ISEN), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Department of Nephrology, Humboldt Universität zu Berlin, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Centre recherche en CardioVasculaire et Nutrition (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de néphrologie, Hôpital Pasteur [Nice] (CHU), Hôpital de Brabois, CHU de Nancy, Vandoeuvre-lès-Nancy, Service de Néphrologie-transplantation-dialyse [Bordeaux], CHU Bordeaux [Bordeaux], Laboratoire des interactions plantes micro-organismes (LIPM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA), CHU Rouen, Normandie Université (NU), Unit Infectious Diseases, Hospital 12 de Octubre, Service de Néphrologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Pédiatrie spécialisée, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Université de Lille, Department of Pulmonary Medicine, Tampere University Hospital, Urgences néphrologiques et transplantation rénale [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Swiss Transplantation Cohort Study, University of Basel (Unibas), Department of Nephrology and Hypertension, and Department of Clinical Research, University of Bern, Centro de Investigación en Ciencias del Mar y Limnología (CIMAR), Universidad Nacional de Costa Rica, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Université de Bordeaux (UB), Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania [Philadelphia], Department of Nephrology and Renal Transplantation, University Hospitals Leuven [Leuven]-Catholic University Leuven, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherches Pétrographiques et Géochimiques (CRPG), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Milano, Université de Lorraine (UL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Laboratory Medicine, Konventhospital Barmherzige Brueder Linz, Clinical Microbiology and Infectious Diseases Department, Universidad Complutense de Madrid [Madrid] (UCM), University Hospitals Leuven [Leuven], Department of Internal Medicine III, Medizinische Universität Wien = Medical University of Vienna, Service de rhumatologie, Kidney and Pancreas Transplantation, Department d'enginyeria quimica agraria i tecnologia agroalimentaria, Universitat de Girona (UdG), Néphrologie Transplantation, Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP), Section of Microbiology [Copenhagen], Department of Biology [Copenhagen], Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU)-Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), University Hospital Basel [Basel], Service Néphrologie Transplantation Rénale, Hôpital Foch [Suresnes], Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION )-Assistance Publique - Hôpitaux de Marseille (APHM), Renal Division, Freiburg University Medical Center, Nephrology Section [Ghent], Ghent University Hospital, Dept. of Nephrology, Institute for Clinical and Experimental Medicine, Division of Infectious Diseases, University of Genoa (UNIGE)-San Martino University Hospital, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université libre de Bruxelles (ULB), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Institut supérieur de l'électronique et du numérique (ISEN)-Université de Valenciennes et du Hainaut-Cambrésis (UVHC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Humboldt University Of Berlin, Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Université de Mons (UMons), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Pennsylvania, Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)-Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Universitäts Klinikum Freiburg = University Medical Center Freiburg (Uniklinik), Università degli studi di Genova = University of Genoa (UniGe)-San Martino University Hospital, ERA-EDTA, ESCMID, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Humboldt-Universität zu Berlin, Institut National de la Recherche Agronomique (INRA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], Service d'Urgences néphrologiques et transplantation rénale [CHU Tenon], Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), and San Martino University Hospital-University of Genoa (UNIGE)

Subjects
Nephrology, Male, Cross-sectional study, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Practice Patterns, 030230 surgery, Antimicrobial stewardship, urologic and male genital diseases, 0302 clinical medicine, Surveys and Questionnaires, Bacteriuria/diagnosis, Medicine, Practice Patterns, Physicians'/statistics & numerical data, Practice Patterns, Physicians', Asymptomatic Infections, Kidney transplantation, ComputingMilieux_MISCELLANEOUS, Asymptomatic bacteriuria, Questionnaire, Transplantation, Urinary tract infection, Adult, Anti-Bacterial Agents, Bacteriuria, Cross-Sectional Studies, Europe, Female, Humans, Kidney Transplantation, Transplant Recipients, Response rate (survey), Kidney Transplantation/adverse effects, 16. Peace & justice, 3. Good health, medicine.medical_specialty, Asymptomatic Infections/epidemiology, Europe/epidemiology, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Dialysis, Physicians', business.industry, medicine.disease, Anti-Bacterial Agents/therapeutic use, Human medicine, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business
Abstract

Background Asymptomatic bacteriuria is frequent in kidney transplant recipients (KTRs). However, there is no consensus on diagnosis or management. We conducted a European survey to explore current practice related to the diagnosis and management of asymptomatic bacteriuria in adult KTRs. Methods A panel of experts from the European Renal Association-European Dialysis Transplant Association/Developing Education Science and Care for Renal Transplantation in European States working group and the European Study Group for Infections in Compromised Hosts of the European Society of Clinical Microbiology and Infectious Diseases designed this cross-sectional, questionnaire-based, self-administered survey. Invitations to participate were e-mailed to European physicians involved in the care of KTRs. Results Two hundred and forty-four participants from 138 institutions in 25 countries answered the survey (response rate 30%). Most participants [72% (176/244)] said they always screen for asymptomatic bacteriuria in KTRs. Six per cent (15/240) reported never treating asymptomatic bacteriuria with antibiotics. When antimicrobial treatment was used, 24% of the participants (53/224) said they would start with empirical antibiotics. For an episode of asymptomatic bacteriuria caused by a fully susceptible microorganism and despite no contraindications, a majority of participants (121/223) said they would use a fluoroquinolone (n = 56), amoxicillin/clavulanic acid (n = 38) or oral cephalosporins (n = 27). Conclusions Screening for and treating asymptomatic bacteriuria are common in KTRs despite uncertainties around the benefits and harms. In an era of antimicrobial resistance, further studies are needed to address the diagnosis and management of asymptomatic bacteriuria in these patients.

Published
2018

34. Pathophysiology CKD 5D

Author

M. Adamczak, A. Wiecek, L. Nowak, A. E. Grzegorzewska, L. Niepolski, D. Pajzderski, W. A. A. A. Mohamed, F. M. Khamis Zaki, W. H. M. Bekhit, I. S. Sherif, C.-C. Lin, H.-Y. Chen, Y.-L. Chiu, S.-P. Hsu, M.-F. Pai, J.-Y. Yang, Y.-S. Peng, T.-J. Tsai, K.-D. Wu, S. Shojai, U. Udayaraj, P. Shojai, R. Zwiech, A. Bruzda-Zwiech, K. Musial, D. Zwolinska, W. Piotr M., A. Mostowska, P. P. Jagodzinski, V. Ortalda, P. Tomei, T. Yabarek, O. Tobaldini, C. Gangemi, M. G. Messa, A. Lupo, L. Ebah, M. Nikam, A. Summers, I. Dawidowska, A. Jayanti, H. Wiig, P. Brenchley, S. Mitra, S. Mikami, T. Hamano, O. Iba, M. Toki, H. Mikami, Y. Takamitsu, M. Fujii, P. Dzekova-Vidimliski, A. Sikole, S. Gelev, G. Selim, L. Trajceska, S. Fujimoto, H. Inagaki, K. Fukudome, F. Ebihara, N. Yokota, Y. Sato, T. Akiba, S. Otsubo, K. Nitta, A. Rydzewska-Rosolowska, J. Gozdzikiewicz, J. Borawski, T. Hryszko, E. Koc-Zorawska, M. Mysliwiec, M. Arias, E. Banon-Maneus, A. Sole, N. Hierro-Garcia, J. Rovira, M. J. Ramirez-Bajo, L. F. Quintana, F. Diekmann, D. Moya-Rull, F. Maduell, J. M. Campistol, M. Erkmen Uyar, S. K. Toprak, H. Saglam, E. Tutal, M. Bay, O. Ilhan, S. Sezer, J. Malyszko, P. Kozminski, and E. Zbroch

Subjects
Transplantation, medicine.medical_specialty, Nephrology, business.industry, Medicine, business, Intensive care medicine, Pathophysiology
Published
2012

37. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients

Author

Tomasz, Hryszko, Alicja, Rydzewska-Rosolowska, Szymon, Brzosko, Ewa, Koc-Zorawska, and Michal, Mysliwiec

Subjects
Aged, 80 and over, Male, Analysis of Variance, Middle Aged, Phosphates, Fibroblast Growth Factors, Molecular Weight, Parathyroid Glands, Fibroblast Growth Factor-23, Parathyroid Hormone, Renal Dialysis, Humans, Kidney Failure, Chronic, Calcium, Female, Iron-Dextran Complex, Prospective Studies, Infusions, Intravenous, Procollagen, Aged
Abstract

Fibroblast growth factor (FGF)-23 inhibits PTH production. Elevated FGF-23 and parathyroid hormone (PTH) levels are characteristic of hemodialyzed patients. Iron polymaltose was shown to increase FGF-23 concentration. The effect of intravenous low molecular weight iron dextran (LMID) on these hormones and bone metabolism has not been studied in hemodialysis (HD). Twelve HD patients were prospectively followed up for 3 weeks after a single infusion of LMID. Calcium, phosphate, FGF-23, PTH, degradation products of C-terminal telopeptides of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were measured prior to, and at week 1 and week 3 after the LMID administration. FGF-23 increased significantly from 453.4 (68.6-3971.5) pg/mL at baseline to 971.8 (779.5-3361.4) pg/mL (P = 0.001) at week 1 and started to decrease toward the initial value at week 3. The changes were accompanied by a significant decline in PTH from 367.6 (21.4-1487.4) pg/mL at baseline to 315.7 (16.4-1339.8) pg/mL (P = 0.018) at week 1 and subsequently began to increase toward the initial values. Phosphate, calcium, CTX and PINP did not change over the study course. LMID causes an increase in FGF-23 concentration together with a decrease in PTH. Our study highlights a pathophysiological element, which may connect suppression of parathyroid glands with intravenous iron supplementation.

Published
2012

42. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II

Author

Jacek, Borawski, Edyta, Zbroch, Alicja, Rydzewska-Rosolowska, Krystyna, Pawlak, and Michal, Mysliwiec

Subjects
Adult, Male, Heparin, Anticoagulants, Humans, Peritoneal Dialysis, Thrombocytopenia, Glycosaminoglycans
Abstract

Heparin-induced thrombocytopenia type II (HIT II) is an immune-mediated prothrombotic state. It requires cessation of all forms of heparin exposure. In maintenance hemodialysis (HD) patients, alternative anticoagulants (i.e. bivalirudin, danaparoid, fondaparinux) may be tried for HD procedure anticoagulation. Sulodexide (SLX) - a purified glycosaminoglycan preparation (80% heparan sulfate and 20% dermatan sulfate) - is not neutralized by platelet factor 4 and may be useful in HIT II. A 32-year-old man on continuous ambulatory peritoneal dilaysis (CAPD) and with protracted atrial fibrillation was given enoxaparin prophylaxis. On day 4, his platelets dropped from 119,000/micronL to 27,000/micronL and HIT II was diagnosed by positive heparin-induced platelet aggregation. While enoxaparin was withdrawn, the platelet count increased and remained stable. In the meantime, atrial fibrillation subsided but the patient developed pseudomonal peritonitis; the catheter was removed and the patient was switched to HD with SLX as an anticoagulant (bolus of 30 mg at HD onset). He was uneventfully treated with HD for 6 weeks and then reverted to CAPD. The widely available and inexpensive SLX may be a new, effective and potentially promising alternative anticoagulant in HD patients with HIT II.

Published
2007

43. FP412THE EFFECT OF ACUTE GFR DECLINE ON SCLEROSTIN, KLOTHO, FGF-23 AND BONE METABOLISM

Author

Szymon Brzosko, Michal Mysliwiec, Katarzyna Kakareko, Pawel Samocik, Tomasz Hryszko, Ewa Koc – Zorawska, Alicja Rydzewska – Rosolowska, Robert Kozlowski, Beata Naumnik, and Joanna Gozdzikiewicz – Lapinska

Subjects
Fibroblast growth factor 23, Transplantation, medicine.medical_specialty, business.industry, Renal function, Bone remodeling, chemistry.chemical_compound, Endocrinology, chemistry, Nephrology, Internal medicine, medicine, Sclerostin, business, Klotho
Published
2015

46. Pathophysiology CKD 5D

Author

Adamczak, M., primary, Wiecek, A., additional, Nowak, L., additional, Grzegorzewska, A. E., additional, Niepolski, L., additional, Pajzderski, D., additional, Mohamed, W. A. A. A., additional, Khamis Zaki, F. M., additional, Bekhit, W. H. M., additional, Sherif, I. S., additional, Lin, C.-C., additional, Chen, H.-Y., additional, Chiu, Y.-L., additional, Hsu, S.-P., additional, Pai, M.-F., additional, Yang, J.-Y., additional, Peng, Y.-S., additional, Tsai, T.-J., additional, Wu, K.-D., additional, Shojai, S., additional, Udayaraj, U., additional, Shojai, P., additional, Zwiech, R., additional, Bruzda-Zwiech, A., additional, Musial, K., additional, Zwolinska, D., additional, Piotr M., W., additional, Mostowska, A., additional, Jagodzinski, P. P., additional, Ortalda, V., additional, Tomei, P., additional, Yabarek, T., additional, Tobaldini, O., additional, Gangemi, C., additional, Messa, M. G., additional, Lupo, A., additional, Ebah, L., additional, Nikam, M., additional, Summers, A., additional, Dawidowska, I., additional, Jayanti, A., additional, Wiig, H., additional, Brenchley, P., additional, Mitra, S., additional, Mikami, S., additional, Hamano, T., additional, Iba, O., additional, Toki, M., additional, Mikami, H., additional, Takamitsu, Y., additional, Fujii, M., additional, Dzekova-Vidimliski, P., additional, Sikole, A., additional, Gelev, S., additional, Selim, G., additional, Trajceska, L., additional, Fujimoto, S., additional, Inagaki, H., additional, Fukudome, K., additional, Ebihara, F., additional, Yokota, N., additional, Sato, Y., additional, Akiba, T., additional, Otsubo, S., additional, Nitta, K., additional, Rydzewska-Rosolowska, A., additional, Gozdzikiewicz, J., additional, Borawski, J., additional, Hryszko, T., additional, Koc-Zorawska, E., additional, Mysliwiec, M., additional, Arias, M., additional, Banon-Maneus, E., additional, Sole, A., additional, Hierro-Garcia, N., additional, Rovira, J., additional, Ramirez-Bajo, M. J., additional, Quintana, L. F., additional, Diekmann, F., additional, Moya-Rull, D., additional, Maduell, F., additional, Campistol, J. M., additional, Erkmen Uyar, M., additional, Toprak, S. K., additional, Saglam, H., additional, Tutal, E., additional, Bay, M., additional, Ilhan, O., additional, Sezer, S., additional, Malyszko, J., additional, Kozminski, P., additional, and Zbroch, E., additional

Published
2012
Full Text
View/download PDF

49. Lack of effect of the CD14 promoter gene C-159T polymorphism on nutritional status parameters in hemodialysis patients

Author

Serwacka, Agnieszka, primary, Protaziuk, Tomasz, additional, Zagozda, Malgorzata, additional, Popow, Anna-Maria, additional, Kierzkiewicz, Maciej, additional, Manitius, Jacek, additional, Mysliwiec, Michal, additional, Daniewska, Dorota, additional, Golebiewski, Sewer, additional, Rydzewska-Rosolowska, Alicja, additional, Flisinski, Mariusz, additional, Stepien, Krystyna, additional, Rydzewska, Grazyna, additional, Olszewski, Waldemar L., additional, and Rydzewski, Andrzej, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results